BostonGene and Exigent Genomic INsight Study
Recruiting · NCT06272864 · Observational (researchers observe without assigning treatment) · Lead sponsor: BostonGene
View the official record on ClinicalTrials.gov →What this trial is about
The BEGIN Study by BostonGene and Exigent Genomic INsight evaluates the efficacy of comprehensive molecular testing in advanced cancer patients. Using the BostonGene Tumor Portrait test, the study aims to identify actionable findings, assess feasibility, and determine patient enrollment in clinical trials. Four cohorts of 100 patients each will be studied over two years, focusing on treatment decisions and patient outcomes. This study seeks to demonstrate the clinical utility of genomic testing in guiding therapy for advanced cancer patients in community settings.
Who can take part
Inclusion criteria
- Patients must have a confirmed malignancy of:
- Locally recurrent, unresectable, or metastatic breast cancer or; Unresectable stage III or metastatic non-small cell lung cancer or; Unresectable or metastatic melanoma or; Locally advanced or metastatic l sarcoma.
- Life expectancy \> 3 months as per the treating physician
- Willingness to provide informed consent
- Living in the United States at time of enrollment
- Agree to participate in genomic and molecular profiling
Exclusion criteria
- not meeting the inclusion criteria
Where it is running
7 locations listed across 7 US states.
- Highlands Oncology Group - Rogers, Arkansas, United States
- Stockton Hematology Oncology Medical Group - Stockton, California, United States
- Fort Wayne Medical Oncology and Hematology - Fort Wayne, Indiana, United States
- New Mexico Cancer Center - Albuquerque, New Mexico, United States
- Oklahoma Cancer Specialists and Research Institute - Tulsa, Oklahoma, United States
- Oncology Consultants - Houston, Texas, United States
- Northwest Medical Specialities - Puyallup, Washington, United States